In some cases, combining intermittent fasting with GLP-1 therapy can be appropriatewhen its medically supervised
Rebosio C, Balbi M, Passalacqua M, Ricciarelli R, Fedele E
These platforms maintain tight control over size distribution (with relative standard deviations under 5 nm) even when scaling flow rates from milliliters to tens of liters per hour
Or we could reduce their dose, improving the toleration of these drugs
Indeed, in the cardiovascular outcome trial (CVOT) for semaglutide, SUSTAIN 6 a relatively short (two-year) and small (3,297 individuals) preregistration trial (an extensive CVOT in obese individuals without T2DM (SELECT) is expected to complete in 2024) HbA 1c was powerfully and durably reduced
So it's worth knowing what to actually look for